另据可靠消息，医渡科技临床循证智能体"医渡智循"已开启内测。据了解，该产品专为临床医生与医学 研究者打造，聚焦临床诊疗和科研场景的真实需求，本次内测邀请具备真实执业背景的一线医生参与， 通过真实执业场景的反馈进一步优化产品临床实用性。此前其打造的"医生Copilot"在单院实现日均被调 用近千次，覆盖了约70%的临床医护人员，成为医生诊疗全程的得力伙伴，"医渡智循"的推出进一步丰 富了其智能体产品矩阵。 当前AI医疗行业政策与技术双轮驱动，国家八部门联合印发的《"人工智能+医疗卫生"应用发展实施意 见》中明确2030年实现二级以上医院智能辅助诊断全覆盖，临床循证类工具成为行业刚需。医渡科技一 边以持续回购传递价值认可，一边加速产品创新落地，其在AI医疗赛道的竞争力持续夯实，长期发展 值得期待。 智通财经APP获悉，2月24日，医渡科技(02158)发布最新股份回购公告：公司当日以每股约5.96港元的 价格回购72万股，总耗资近430万港元，延续2026年以来的密集回购节奏。自1月26日以来，公司已完成 17次回购，累计斥资超7200万港元，以持续的资本动作彰显对自身发展及行业前景的双重信心。 ...

Core Viewpoint - The company, Yidu Tech (02158), demonstrates confidence in its development and industry prospects through continuous share buybacks and product innovation in the AI healthcare sector [1]. Group 1: Share Buyback Activity - On February 24, Yidu Tech announced a share buyback of 720,000 shares at approximately HKD 5.96 per share, totaling nearly HKD 4.3 million [1]. - Since January 26, the company has completed 17 buybacks, with a cumulative expenditure exceeding HKD 72 million, reflecting a strong commitment to shareholder value [1]. Group 2: Product Development - Yidu Tech's clinical evidence-based AI tool, "Yidu Zhixun," has entered internal testing, aimed at clinical doctors and medical researchers, focusing on real-world clinical and research needs [1]. - The internal testing involves frontline doctors with real practice backgrounds to optimize the product's clinical usability based on actual feedback [1]. - The previously developed "Doctor Copilot" tool has been utilized nearly 1,000 times daily in a single hospital, covering about 70% of clinical healthcare personnel, indicating strong product adoption [1]. Group 3: Industry Context - The AI healthcare industry is driven by both policy and technology, with a joint issuance from eight national departments outlining plans for full coverage of intelligent diagnostic assistance in secondary hospitals by 2030 [1]. - Clinical evidence-based tools are becoming essential in the industry, positioning Yidu Tech favorably as it continues to innovate and reinforce its competitive edge in the AI healthcare sector [1].

Core Viewpoint - The company, Yidu Tech (02158), is actively repurchasing shares, signaling confidence in its value and positively impacting market sentiment [1] Group 1: Share Buyback Activity - On February 9, Yidu Tech announced a share buyback, repurchasing 910,000 shares at approximately HKD 5.77 per share, totaling over HKD 5 million [1] - This marks the company's eleventh consecutive trading day of intensive buybacks, with a cumulative repurchase amount of approximately HKD 58 million [1] - The stock price of Yidu Tech rose by 3.39% on the same day, closing at HKD 5.79, reflecting a positive market response to the buyback [1] Group 2: Analyst Ratings and Market Position - Citigroup maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11 [1] - The company has established a strong presence in national-level AI medical application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions [1] - Yidu Tech's products, such as the Doctor Copilot, and its consumer-facing offering "Yidu Qianyu" demonstrate solid technical capabilities, performing well in accuracy and traceability of medical evidence in tests conducted by Citigroup [1] - The company is positioned in the first tier alongside leading products like Ant Group's "Alfu" and iFlytek's "Xiao Yi," creating a synergistic layout between its To-G (government and hospital) and To-C (consumer) business segments [1]

近日，花旗发布研报，维持医渡科技"买入"评级，并将其目标价上调至11港元。研报指出，医渡科技已 深度嵌入北京、河南等地的国家级AI医疗应用试点基地项目，并打造了医生Copilot等产品显著提升了 医疗机构运营效率，减轻医护人员负担。与此同时，公司在面向C端推出的"医渡千愈"亦展现出扎实的 技术功底，在花旗开展的多场景测试中，其回答的准确性与医学证据可追溯性表现突出，与蚂蚁阿福、 讯飞晓医等头部产品同处第一梯队，形成To-G(面向政府与医院)与To-C业务的协同布局，为公司长期发 展筑牢根基。 智通财经APP获悉，2月9日，医渡科技(02158)发布最新股份回购公告：公司当日以每股约5.77港元的价 格回购91万股，总耗资超500万港元，实现连续第十一个交易日密集回购，累计回购金额约5800万港 元，以持续的资本动作传递对公司价值的认可。 同日港股收盘数据显示，医渡科技股价上涨3.39%，收盘价格报5.79港元，股价同步回暖与连续回购形 成正向呼应，反映市场情绪逐步提振。 ...

Core Viewpoint - Citigroup maintains a "Buy" rating for Yidu Tech (02158) and raises its target price to HKD 11, anticipating a potential upside of over 96% for the stock [1] Group 1: Company Positioning - Yidu Tech is positioned as a leading player in the domestic AI healthcare sector, leveraging favorable policies, deep industry experience, and a comprehensive product layout to secure a core position in the wave of AI infrastructure development in healthcare [1] - The company has embedded itself in national-level AI healthcare application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions and alleviating the burden on healthcare personnel through products like Doctor Copilot [1] Group 2: Policy and Market Opportunities - The macro policy push for "AI + Healthcare" in China provides a clear growth path for Yidu Tech, with plans to establish multiple national pilot bases by 2027 and achieve widespread AI technology coverage in secondary hospitals by 2030 [1] - The company's WeChat mini-program "Yidu Qianyu" demonstrates solid technical capabilities, ranking among the top tier in accuracy and traceability during scenario tests conducted by Citigroup, thus supporting both To-G (government and hospitals) and To-C (consumer) business models [1] Group 3: Financial Projections - Citigroup recognizes Yidu Tech's substantial accumulation in medical data governance and knowledge construction, attributing its unique advantage to the large-scale, high-quality data sourced from top hospitals [2] - The company's government and hospital-facing business segments show more predictable profitability, benefiting directly from increased AI budgets in hospitals and national project tenders [2] - Citigroup has adjusted its financial forecasts for Yidu Tech, expecting revenue from its big data platform to grow by 17% and 30% year-on-year in fiscal years 2026 and 2027, respectively, with a potential break-even point in fiscal year 2026 [2]

Core Viewpoint - Citigroup maintains a "Buy" rating for Yidu Tech (02158) and raises its target price to HKD 11, indicating a potential upside of over 96% for the stock [1] Group 1: Company Positioning - Yidu Tech is positioned as a leading player in the domestic AI healthcare sector, leveraging favorable policies, deep industry experience, and a comprehensive product layout to secure a core position in the wave of healthcare AI infrastructure development [1] - The company has embedded itself in national AI healthcare application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions through products like Doctor Copilot [1] Group 2: Policy and Market Opportunities - The macro policy push for "AI + Healthcare" in China provides a clear growth path for Yidu Tech, with plans to establish multiple national pilot bases by 2027 and achieve widespread AI technology coverage in secondary hospitals by 2030 [1] - The company's WeChat mini-program "Yidu Qianyu" demonstrates strong technical capabilities, ranking alongside top products in accuracy and traceability, thus supporting both To-G (government and hospitals) and To-C (consumer) business models [1] Group 3: Financial Projections - Citigroup recognizes Yidu Tech's substantial accumulation in medical data governance and knowledge construction, attributing unique advantages to the quality and authority of its data sourced from top hospitals [2] - The company's To-G business segment shows more predictable profitability compared to consumer applications, benefiting directly from increased hospital AI budgets and national project tenders [2] - Financial forecasts have been adjusted, with expectations for the big data platform revenue to grow by 17% and 30% year-on-year in fiscal years 2026 and 2027, respectively, with a potential break-even point in fiscal year 2026 [2]

Core Viewpoint - Citigroup maintains a "Buy" rating for Yidu Tech and raises its target price to HKD 11, anticipating a potential upside of over 96% for the stock [1] Group 1: Company Positioning - Yidu Tech is positioned as a leading player in the domestic AI healthcare sector, leveraging favorable policies, deep industry experience, and a comprehensive product portfolio to secure a core position in the wave of healthcare AI infrastructure development [1] - The company has embedded itself in national AI healthcare application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions and alleviating the burden on healthcare personnel through products like Doctor Copilot [1] Group 2: Policy and Market Opportunities - The macro policy push for "AI + Healthcare" in China provides a clear growth path for Yidu Tech, with plans to establish multiple national pilot bases by 2027 and achieve widespread AI technology coverage in secondary hospitals by 2030 [1] - The company's WeChat mini-program "Yidu Qianyu" demonstrates solid technical capabilities, ranking alongside top products in accuracy and traceability, thus supporting both To-G (government and hospitals) and To-C (consumer) business models [1] Group 3: Financial Projections - Citigroup recognizes Yidu Tech's strong foundation in medical data governance and knowledge construction, attributing its unique advantage to the large scale and quality of data sourced from top hospitals [2] - The company's To-G business segment shows more predictable profitability compared to consumer applications, benefiting directly from increased hospital AI budgets and national project tenders [2] - Citigroup has adjusted its financial forecasts for Yidu Tech, projecting a 17% and 30% year-on-year growth in big data platform revenue for fiscal years 2026 and 2027, respectively, with a potential break-even point in fiscal year 2026 [2]

Core Insights - The "2025 Fifth China Health Industry Development and Rehabilitation Service Conference" was successfully held in Beijing, focusing on integrating resources across the health industry and exploring development paths under the theme "Intelligent Leadership for a Healthy Future" [1] Group 1: Industry Trends and Innovations - The conference featured high-level roundtable discussions on cutting-edge topics such as innovative drugs, brain-machine interfaces, AI in healthcare, and the transformation of traditional Chinese medicine [1] - A series of innovative case studies were released, showcasing advancements in areas like ESG, innovative drugs, biomedicine, AI healthcare, and social psychological services, highlighting the vitality and innovation within the health sector [1] Group 2: Company Highlights - **Jingtai Holdings** utilizes "AI + Robotics + Data" to accelerate drug development, having collaborated with major pharmaceutical companies and significantly expedited the market entry of Pfizer's COVID-19 oral drug Paxlovid by six months [3] - **Meinian Health** leverages AI technology for precise early screening and health management, continuously launching specialized products to meet diverse public health management needs [4] - **Dean Diagnostics** has developed an AI product matrix that enhances medical scene intelligence, achieving comprehensive coverage from hospitals to personal health management [5] - **Yingkang Life** integrates AI deeply into the entire medical service process, significantly improving medical capabilities and operational efficiency through its AI-driven platforms [6][7] - **New Mile Health Technology** is advancing a smart healthcare system that combines online and offline services, enhancing the digital landscape of managed healthcare [8] - **Airdoc** focuses on retinal AI imaging technology for chronic disease early screening and management, having provided diagnostic solutions to over 30 million people [9] - **Aidikang** employs AI-assisted imaging to enhance detection efficiency, achieving a performance rate of 6-7 times that of manual processes in key medical fields [10] - **Yidu Technology** has introduced the "Doctor Copilot" AI platform, which integrates seamlessly into clinical workflows, significantly enhancing the efficiency of healthcare services [11] - **Deepwise Medical** offers multi-modal AI solutions to various healthcare institutions, supporting high-quality development across the medical sector [12] - **Huadensen Bio** focuses on "precision diagnosis" through liquid biopsy technology, utilizing AI to improve the efficiency and accuracy of CTC detection [14]

Core Viewpoint - In the context of ongoing adjustments in the Hong Kong stock market, Yidu Tech (02158) has demonstrated its intrinsic value and management confidence through a series of solid buyback operations and significantly improved interim performance [1] Buyback Operations - On December 9, Yidu Tech announced a buyback of 345,000 shares at a price of HKD 5.15 per share, amounting to approximately HKD 1.78 million [1] - The company has implemented buybacks for five consecutive trading days, totaling around 1.42 million shares and exceeding HKD 7.3 million in total buyback amount [1] Financial Performance - For the interim results of the fiscal year 2026, Yidu Tech reported total revenue of RMB 358 million, representing a year-on-year growth of 8.7% [1] - The adjusted EBITDA for existing business reached approximately RMB 54 million, doubling compared to the same period last year, with the company nearing breakeven on the accounting level, achieving this milestone about a year ahead of management's original expectations [1] Market and Industry Trends - According to Guosen Securities, the short-term adjustment in the Hong Kong stock market provides space for recovery in 2026 [1] - The US dollar index is expected to weaken in early 2026, benefiting the valuation recovery of emerging markets [1] - The AI sector remains a key focus for 2026, driven by the need for accelerated domestic hardware production and the anticipation of more AI applications [1] AI Medical Sector - Yidu Tech operates in the AI medical sector, which is one of the most barrier-protected and demand-driven core scenarios in the "AI empowering various industries" trend [1] - The company's medical large model technology has entered a new phase of "multiple blooming and large-scale landing," evidenced by three dimensions: 1. Deep application in well-known hospitals, with the AI middle platform implemented in over 30 top-tier hospitals, achieving nearly 1,000 high-frequency calls per day in a single hospital [1] 2. Significant improvement in the accuracy of the TNM staging assessment intelligent agent for key specialties [1] 3. Integration of expert wisdom through the digital twin of doctors, allowing broader service of clinical experience to patients [1]

Core Viewpoint - In the context of ongoing adjustments in the Hong Kong stock market, Yidu Tech (02158) has demonstrated its intrinsic value and management confidence through a series of solid buyback operations and significantly improved interim performance [1] Group 1: Buyback Operations - On December 9, Yidu Tech announced a buyback of 345,000 shares at a price of HKD 5.15 per share, totaling approximately HKD 1.78 million [1] - The company has implemented buybacks for five consecutive trading days, accumulating around 1.42 million shares with a total expenditure exceeding HKD 7.3 million [1] Group 2: Financial Performance - For the interim report of the fiscal year 2026, Yidu Tech reported total revenue of RMB 358 million, representing a year-on-year growth of 8.7% [1] - The adjusted EBITDA for existing business reached approximately RMB 54 million, doubling compared to the same period last year, with the company nearing breakeven on its financial statements, achieving this milestone about a year ahead of management's original expectations [1] Group 3: Market and Industry Trends - According to Guosen Securities, the short-term adjustment in the Hong Kong stock market provides space for recovery in 2026, with the US dollar index expected to weaken in early 2026, benefiting the valuation recovery of emerging markets [1] - The AI sector remains a key focus for 2026, driven by the need for accelerated domestic hardware production and the anticipation of more AI applications, with companies increasingly utilizing AI to enhance labor productivity [1] Group 4: Company Positioning in AI Healthcare - Yidu Tech operates in the AI healthcare sector, which is one of the most barrier-rich and demand-driven core scenarios in the "AI empowering various industries" landscape [1] - The company's medical large model technology has entered a new phase of "multiple blooming and large-scale implementation," evidenced by three dimensions: deep application in over 30 top-tier hospitals, significant accuracy improvements in TNM staging assessment, and the integration of expert clinical experience through digital avatars of doctors [1]